<DOC>
	<DOCNO>NCT00322569</DOCNO>
	<brief_summary>To demonstrate non-inferiority 6-month angiographic in-stent late lumen loss pimecrolimus-eluting coronary stent ( Corio ) compare CoStar coronary stent control arm dual pimecrolimus/paclitaxel-eluting ( Symbio ) coronary stent compare CoStar coronary stent control arm treatment single de novo lesion &lt; 25 mm length native coronary artery 2.5 - 3.5 mm diameter .</brief_summary>
	<brief_title>A Randomized , Multi-Center Study Pimecrolimus-Eluting Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems ( GENESIS )</brief_title>
	<detailed_description>This study design evaluate 6 month in-stent late lumen loss 1 ) Corio™ pimecrolimus-eluting coronary stent system 2 ) SymBio™ dual pimecrolimus/paclitaxel-eluting coronary stent system compare CoStar™ Paclitaxel-Eluting Coronary Stent System control arm .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>General Inclusion Criteria 1 . Eligible percutaneous coronary intervention ( PCI ) . 2 . Documented stable unstable angina pectoris 3 . Left ventricular ejection fraction ( LVEF ) ≥25 % 4 . Acceptable candidate coronary artery bypass graft surgery ( CABG ) . 5 . Target lesion &lt; 25 mm length RVD ≥2.5 mm ≤3.5 mm visually estimate stenosis ≥50 % &lt; 100 % . 6 . Target vessel undergone prior revascularization within precede 6 month . 7 . Target lesion must minimum 10 mm distance previously treat segment target vessel 8 . Patient understood study requirement treatment procedure provide write Informed Consent , approve local Ethics Committee . 9 . Willing comply specify followup evaluation . General Exclusion Criteria 1 . Known sensitivity pimecrolimus , paclitaxel , polymer ( PLGA ) cobalt chromium . 2 . Planned treatment PCI device target vessel ( ) . 3 . MI within 72 hour prior index procedure 4 . The patient cardiogenic shock . 5 . Cerebrovascular Accident ( CVA ) within past 6 month . 6 . Acute chronic renal dysfunction 7 . Contraindication ASA clopidogrel . 8 . Thrombocytopenia 9 . Active gastrointestinal ( GI ) bleed within past 3 month . 10 . Any prior true anaphylactiod reaction contrast agent 11 . Patient currently take colchicine , chronic systemic steroid therapy systemic immunosuppressant therapy , treat paclitaxel ( systemic ) within 12 month index procedure . 12 . Patient currently , long term intermittent therapy topical pimecrolimus 13 . Female childbearing potential . 14 . Life expectancy le 24 month due medical condition . 15 . Comorbid condition ( ) 16 . Currently participate another investigational drug device study General Angiographic 1 . Left main coronary artery disease ( stenosis &gt; 50 % ) , whether protect unprotected . 2 . Target lesion ostial location ( within 3.0 mm vessel origin ) . 3 . Target lesion and/or target vessel proximal target lesion severely calcify visual estimation . 4 . Target lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch vessel &gt; 2.0 mm diameter require intervention . 5 . Target lesion totally occluded Thrombolysis In MI ( TIMI flow 0 ) TIMI flow ≤1 . 6 . Angiographic presence probable definite thrombus . 7 . Target vessel would pretreated unapproved device , directional rotational coronary atherectomy , laser , cut balloon transluminal extraction catheter immediately prior stent placement . 8 . Prior coronary intervention use brachytherapy segment target vessel . 9 . The target vessel prior drugeluting stent placement vessel segment ( branch ) proximal intend target lesion site within precede 6 month . 10 . Angiographic restenosis segment target vessel undergone prior percutaneous coronary intervention . 11 . Angiographic evidence atherosclerotic disease &gt; 50 % diameter stenosis ( visual estimate ) proximal distal target lesion ( applies major epicardial portion target vessel contiguous vessel segment target lesion locate branch vessel ) . 12 . Prior surgical revascularization target vessel patent graft ( saphenous vein graft arterial conduit ) . 13 . Target lesion lie within 10mm prior surgical anastomosis site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Percutaneous coronary intervention ( PCI )</keyword>
	<keyword>Drug elute stent ( DES )</keyword>
</DOC>